HYDERABAD: Pharma major Aurobindo Pharma Ltd has posted a nearly 9% rise in consolidated net profit for the quarter ended Sept 30,2024, at Rs 817 crore as compared to Rs 752 crore in the corresponding quarter of last financial year.
This was on an 8% increase in consolidated revenue from operations for Q2FY25 at Rs 7796 crore from Rs 7219 crore in Q2FY24.
Revenues from formulations grew 11.3% to Rs 6640 crore during Q2FY25 from Rs 5968 crore with US market (excluding Puerto Rico) accounting for a 4.3% revenue increase to Rs 3530 crore from Rs 3385 crore and that from European formulations revenues rising 19% to Rs 2105 crore.
While revenues from growth markets soared 44% to Rs 812 crore, that from ARV (anti-retrovirals) fell nearly 23% to Rs 193 crore from Rs 250 crore.
In terms of active pharmaceutical ingredients, revenues declined marginally by around 1% to Rs 1156 crore from Rs 1166 crore with revenues from beta-lactam APIs growing 2.5% to Rs 837 crore and that from non beta-lactam APIs falling nearly 9% to Rs 319 crore.
The company said it had received final approval for eight abbreviated new drug applications during the quarter from the US Food and Drug Administration and launched 14 products during the quarter.
With this, the company has received 676 final approvals and 26 tentative approvals from the US drug watchdog.
Commenting on the performance, Aurobindo Pharma vice-chairman & managing director K Nithyananda Reddy said: “We are pleased with the continued growth in revenues across our key business areas this quarter, reflecting the resilience of our diversified portfolio. While profitability saw a slight dip, primarily due to the transient nature of certain business activities, our underlying performance remains strong. With a solid foundation and ongoing operational improvements, we are confident of maintaining our growth trajectory and achieving our strategic objectives for the year.”
